The European Medicines Agency has approved two new Covid-19 treatments: an antibody medication and an arthritis drug that turned out to be able to “reduce” the inflammation associated with the virus.
The first drug, Xevudy, produced by GlaxoSmithKline and Vir Biotechnology was recommended for treating the virus in adults and adolescents older than 12 who weigh at least 40 kilograms and ”Who do not need supplemental oxygen, and who have a greater chance of getting the disease severe.”
Xevudy, which is the third monoclonal immunotherapy treatment that has been approved by the EU following Ronapreve or Regkirona.
Sobi in Sweden produces Kineret. This immunosuppressive medicine is being used as a treatment for inflammatory diseases.
“Covid-19 patients are treated with the medicine to lower inflammation. [the virus]You can prevent the development of severe breathing problems by reducing lower airway damage.,” the EMA said.
It is recommended for adult Covid patients with pneumonia who require supplemental oxygen and “Who are at high risk for severe and persistent respiratory problems.”
So far, six Covid-19 treatments have been approved by regulators. In an effort to reduce the spread of Omicron, the regulator is currently looking at other options. Those under consideration include Pfizer’s Paxlovid and Merck’s Lagevrio.
Head of UK’s Antiviral Taskforce, David Jones said that both these drugs would be readily available in the UK during winter.
The European Commission states that the Omicron version will be the dominant variant in the EU from mid-January.